Pieris cuts 70% of workforce as AstraZeneca terminates tie-up
2023-07-18
临床2期临床失败
Pieris Pharmaceuticals announced on Tuesday that it would cut around 70% of its staff and explore strategic options due to events that have impacted its inhaled respiratory franchise, including AstraZeneca's discontinuation of a Phase IIa study for elarekibep in asthma. The company added that the UK drugmaker has now decided to terminate its agreement for the IL-4 receptor alpha inhibitorIL-4 receptor alpha inhibitor, which was signed in 2017, handing back rights to the inhaled Anticalin therapy.
"We are pursuing strategic options across three main areas," explained CEO Stephen Yoder, adding that "one track is accelerating partnering discussions of PRS-220 and PRS-400," which are inhaled Anticalin proteins in preclinical trials for respiratory diseases. The company is also focused on selecting a development partner and deal structure to re-initiate clinical development of its former lead immuno-oncology asset cinrebafusp alfa.
The drug, also known as PRS-343, has shown potential in a HER2+ gastric cancer trial, but "was discontinued for strategic reasons" last year. Yoder added "third, we will explore whether our balance sheet, position as a public company, and other assets are of strategic value to a range of third parties."
Pieris currently has cash, cash equivalents and investments totalling $54.9 million, with the workforce cuts set to reduce cash spending. The company noted that it does not intend to make any further disclosures regarding the strategic review process until a specific course of action has been decided.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。